H.C. Wainwright has downgraded Carisma Therapeutics (NASDAQ:CARM) to neutral from buy, citing the company’s discontinuation of a second lead program within a year.
The investment bank noted that Carisma (NASDAQ:CARM) said its decision to discontinue development of CT-0525 was
